Molecular Therapy
The Molecular Therapy family of journals are ASGCT's official journals

View the family homepage Submit Your Research

Claim Your Molecular Therapy Subscription

ASGCT members receive online subscriptions to the Molecular Therapy journals to stay up to date on the latest research in the field. Here's how to claim your subscription:

  1. Sign into your ASGCT account.

  2. Navigate to the Membership Dashboard.

  3. Click on the Molecular Therapy link.

Molecular Therapy Family

Molecular Therapy

MT is dedicated to publishing important peer-reviewed research and cutting-edge reviews and commentaries promoting genetics, medicine, and biotechnology.

Molecular Therapy Methods & Clinical Development

MTMCD focuses on advances in cell and gene therapy and how they are translated and applied in the clinical setting.

Molecular Therapy Nucleic Acids

MTNA publishes top-quality basic, translational, and clinical research in the broad fields of nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease.

Molecular Therapy Oncology

MTO focuses on the development and testing of cancer therapies in pre-clinical and clinical settings, and provides a unique forum for work in the burgeoning fields of biologic cancer therapies including viral, bacterial, cellular, and gene therapy.

MT Quick Links

Aims and Scope

Learn more about and submit your research to any of the four journals.

Editorial Contacts

Contact the editors-in-chief of each journal as well as Cell Press communications and advertising staff here.

Permissions

Want to request permission to use information in Molecular Therapy? Here's how to submit a request.

Ethical Statements

Read Molecular Therapy's ethical statements on authorship, dual submission, competing interests, inclusion and diversity, and more.

2025

Class Considerations on Immunogenicity for AAV GT Products

January 22-23, 2025 | Virtual

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.